Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arginine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OTC | P00480 | 1/20 | 0.50 |
| ▸ | NOS2 | P35228 | 8/20 | 0.49 |
| ▸ | NOS1 | P29475 | 8/20 | 0.49 |
| ▸ | NOS3 | P29474 | 6/20 | 0.49 |
| ▸ | DDAH1 | O94760 | 3/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arginine SCHEMBL5544125 | 1.00 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL1675351 | 1.00 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL9754275 | 1.00 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL5544129 | 1.00 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL1821002 | 1.00 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL2397458 | 1.00 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL5312506 | 1.00 | OTC (0.50) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL15323423 | 0.97 | OTC (0.48) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL11018148 | 0.97 | OTC (0.48) | OTCNOS2NOS1NOS3DDAH1 | |
| Arginine SCHEMBL15323426 | 0.97 | OTC (0.48) | OTCNOS2NOS1NOS3DDAH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9091700-B2 | Modified peptide substrate | MCMASTER UNIVERSITY (CA) | 2015-07-28 | — | — | US | claimed |
| US-20120208225-A1 | MODIFIED PEPTIDE SUBSTRATE | THE UNIVERSITY OF MELBOURNE (AU) | 2012-08-16 | — | — | US | claimed |
| EP-1498476-B1 | MUTATED ALKALINE CELLULASE | KAO CORP (JP) | 2008-10-15 | — | — | EP | claimed |
| US-7364891-B2 | Mutated alkaline cellulase | KAO CORPORATION (JP) | 2008-04-29 | — | — | US | claimed |
| US-20050287656-A1 | Mutated alkaline cellulase | KAO CORPORATION (JP) | 2005-12-29 | — | — | US | claimed |
| EP-1498476-A1 | MUTATED ALKALINE CELLULASE | Kao Corporation (JP) | 2005-01-19 | — | — | EP | claimed |
| WO-1991015584-A1 | TRYPANOSOMA CRUZI RECOMBINANT ANTIGENS AND SYNTHETIC PEPTIDES FOR UTILIZATION IN THE IMMUNOLOGICAL DIAGNOSIS OF CHAGAS DISEASE | Fundação Oswaldo Cruz (Fiocruz) (BR) | 1991-10-17 | — | — | WO | claimed |
| US-10131932-B2 | Method for assaying a protease | MCMASTER UNIVERSITY | 2018-11-20 | — | — | US | disclosed |
| EP-3047033-B1 | METHOD FOR ASSAYING A PROTEASE | UNIV MCMASTER (CA) | 2018-08-22 | — | — | EP | disclosed |
| US-20160326569-A1 | METHOD FOR ASSAYING A PROTEASE | MCMASTER UNIVERSITY (CA) | 2016-11-10 | — | — | US | disclosed |
| EP-3047033-A1 | METHOD FOR ASSAYING A PROTEASE | Mcmaster University (CA) | 2016-07-27 | — | — | EP | disclosed |
| US-9091700-B2 | Modified peptide substrate | MCMASTER UNIVERSITY (CA) | 2015-07-28 | — | — | US | disclosed |
| WO-2015039211-A1 | METHOD FOR ASSAYING A PROTEASE | MCMASTER UNIVERSITY (CA) | 2015-03-26 | — | — | WO | disclosed |
| US-20120208225-A1 | MODIFIED PEPTIDE SUBSTRATE | THE UNIVERSITY OF MELBOURNE (AU) | 2012-08-16 | — | — | US | disclosed |
| US-20100068692-A1 | ANTIFREEZE GLYCOPROTEIN ANALOGUES AND USES THEREOF | UNIVERSITY OF OTTAWA (CA) | 2010-03-18 | — | — | US | disclosed |
| EP-1498476-B1 | MUTATED ALKALINE CELLULASE | KAO CORP (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-7364891-B2 | Mutated alkaline cellulase | KAO CORPORATION (JP) | 2008-04-29 | — | — | US | disclosed |
| US-20050287656-A1 | Mutated alkaline cellulase | KAO CORPORATION (JP) | 2005-12-29 | — | — | US | disclosed |
| EP-1498476-A1 | MUTATED ALKALINE CELLULASE | Kao Corporation (JP) | 2005-01-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100068692-A1 | ANTIFREEZE GLYCOPROTEIN ANALOGUES AND USES THEREOF | SRRM2, MSR1, CD59 | OTC 518/4885NOS2 78/4885NOS1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.